PMC:7283670 / 124130-124362
Annnotations
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T676 | 44-48 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T677 | 163-179 | Disease | denotes | viral infections | http://purl.obolibrary.org/obo/MONDO_0005108 |
LitCovid-PD-GO-BP
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T18 | 163-179 | http://purl.obolibrary.org/obo/GO_0016032 | denotes | viral infections |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1032 | 0-232 | Sentence | denotes | Other candidates for possible management of SARS‐CoV‐2 include Leronlimab and Galidesivir, both of which have been of clinical value in treatment of several fatal viral infections, and were shown to improve the survival of patients. |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 2544 | 44-54 | Species | denotes | SARS‐CoV‐2 | Tax:2697049 |
| 2545 | 223-231 | Species | denotes | patients | Tax:9606 |
| 2549 | 63-73 | Chemical | denotes | Leronlimab | MESH:C420063 |
| 2550 | 78-89 | Chemical | denotes | Galidesivir | MESH:C517546 |
| 2552 | 163-179 | Disease | denotes | viral infections | MESH:D001102 |